Table 7 Statistics of treatment response and length of hospital stay stratified by both TANDEM size and drug-loading concentration.

From: The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment

 

TANDEM size

P-valuea

75 μm

100 μm

Half-loaded (Group 1, n = 4)

Full-loaded (Group 2, n = 22)

Half-loaded (Group 3, n = 11)

Full-loaded (Group 4, n = 50)

Treatment response

    

0.020

CR

1 (25.0%)

6 (27.3%)*

7 (63.6%)

9 (18.0%)‡

 

PR

0 (0.0%)

11 (50.0%)

3 (27.3%)

18 (36.0%)

 

SD

3 (75.0%)

3 (13.6%)

1 (9.1%)

11 (22.0%)

 

PD

0 (0.0%)

2 (9.1%)

0 (0.0%)

12 (24.0%)

 

ORR

    

0.016

Yes (CR + PR)

1 (25.0%)

17 (77.3%)

10 (90.9%)*

27 (54.0%)‡

 

No (SD + PD)

3 (75.0%)

5 (22.7%)

1 (9.1%)

23 (46.0%)

 

DCR

    

0.144

Yes (CR + PR + SD)

4 (100.0%)

20 (90.9%)

11 (100.0%)

38 (76.0%)

 

No (PD)

0 (0.0%)

2 (9.1%)

0 (0.0%)

12 (24.0%)

 

Length of hospital stay (days)

2.0 ± 2.0

3.0 ± 1.9

1.6 ± 1.3

4.2 ± 2.3†,‡

 < 0.001

  1. Treatment response, ORR and DCR were resented as number and percentage.
  2. Length of hospital stay were presented as mean ± SD (days).
  3. aFisher's exact test and Kruskall-Wallis test was performed for treatment response and length of hospital stay, respectively.
  4. *P < 0.05 compared to Group 1 by Fisher's exact test for treatment response and Mann–Whitney test for length of hospital stay.
  5. †P < 0.05 compared to Group 2 by Fisher's exact test for treatment response and Mann–Whitney test for length of hospital stay.
  6. ‡P < 0.05 compared to Group 3 by Fisher's exact test for treatment response and Mann–Whitney test for length of hospital stay.
  7. CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate.
Back to article page